These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 34189948)

  • 1. Indications for and contraindications of immune checkpoint inhibitors in cancer patients with COVID-19 vaccination.
    Luo B; Li J; Hou X; Yang Q; Zhou Y; Ye J; Wu X; Feng Y; Hu T; Xu Z; He Y; Sun J
    Future Oncol; 2021 Sep; 17(26):3477-3484. PubMed ID: 34189948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mRNA COVID-19 vaccine in patients with cancer receiving checkpoint inhibitor therapy: what we know and what we don't.
    Malek AE; Cornejo PP; Daoud N; Alam M
    Immunotherapy; 2022 Feb; 14(2):91-94. PubMed ID: 34747190
    [No Abstract]   [Full Text] [Related]  

  • 3. COVID-19 vaccination in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis.
    Ruiz JI; Lopez-Olivo MA; Geng Y; Suarez-Almazor ME
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36746512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overlap of immunotherapy-related pneumonitis and COVID-19 pneumonia: diagnostic and vaccine considerations.
    Abid MB
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influenza vaccination in cancer patients receiving immune checkpoint inhibitors: A systematic review.
    Spagnolo F; Boutros A; Croce E; Cecchi F; Arecco L; Tanda E; Pronzato P; Lambertini M
    Eur J Clin Invest; 2021 Jul; 51(7):e13604. PubMed ID: 34021591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of immune checkpoint therapy for patients with cancer in the face of COVID-19.
    Shen C; Li Q; Wei Y; Li Y; Li J; Tao J
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33303577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors.
    Terpos E; Zagouri F; Liontos M; Sklirou AD; Koutsoukos K; Markellos C; Briasoulis A; Papanagnou ED; Trougakos IP; Dimopoulos MA
    J Hematol Oncol; 2021 May; 14(1):86. PubMed ID: 34059088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of COVID-19 vaccines in subjects with solid tumor cancers receiving immune checkpoint inhibitors.
    Gilbert D; Hu J; Medina T; Kessler ER; Lam ET
    Hum Vaccin Immunother; 2023 Dec; 19(1):2207438. PubMed ID: 37157982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune responses to COVID-19 vaccines in patients with cancer: Promising results and a note of caution.
    Griffiths EA; Segal BH
    Cancer Cell; 2021 Aug; 39(8):1045-1047. PubMed ID: 34242573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune-Related Adverse Events Among COVID-19-Vaccinated Patients With Cancer Receiving Immune Checkpoint Blockade.
    Widman AJ; Cohen B; Park V; McClure T; Wolchok J; Kamboj M
    J Natl Compr Canc Netw; 2022 Oct; 20(10):1134-1138. PubMed ID: 36240845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of COVID-19 Vaccination in Melanoma Patients under Immune Checkpoint Blockade.
    Niewolik J; Mikuteit M; Cossmann A; Vahldiek K; Gutzmer R; Müller F; Schröder D; Heinemann S; Behrens GMN; Dopfer-Jablonka A; Steffens S; Grimmelmann I
    Oncology; 2022; 100(7):392-398. PubMed ID: 35609553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 vaccination and cancer immunotherapy: should they stick together?
    Brest P; Mograbi B; Hofman P; Milano G
    Br J Cancer; 2022 Jan; 126(1):1-3. PubMed ID: 34799696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2 infection and COVID-19 vaccination in cancer patients undergoing immune checkpoint inhibitors.
    Yang Y; Xu G
    Cell Death Dis; 2023 Jun; 14(6):390. PubMed ID: 37391394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiotoxicity of Immune Checkpoint Inhibitors.
    Patel RP; Parikh R; Gunturu KS; Tariq RZ; Dani SS; Ganatra S; Nohria A
    Curr Oncol Rep; 2021 May; 23(7):79. PubMed ID: 33937956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment.
    Strobel SB; Machiraju D; Kälber KA; Hassel JC
    Cancer Immunol Immunother; 2022 Aug; 71(8):2051-2056. PubMed ID: 34940894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 vaccination: Recommendations for management of patients with allergy or immune-based diseases.
    Peter J
    S Afr Med J; 2021 Feb; 111(4):291-294. PubMed ID: 33944757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rethinking the management of immune checkpoint inhibitor-related adrenal insufficiency in cancer patients during the COVID-19 pandemic.
    Yuen KCJ; Mortensen MJ; Azadi A; Fonkem E; Findling JW
    Endocrinol Diabetes Metab; 2021 Jul; 4(3):e00246. PubMed ID: 34268454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type 1 Diabetes Mellitus Associated with Nivolumab after Second SARS-CoV-2 Vaccination, Japan.
    Sato T; Kodama S; Kaneko K; Imai J; Katagiri H
    Emerg Infect Dis; 2022 Jul; 28(7):1518-1520. PubMed ID: 35468049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition.
    Rogiers A; Pires da Silva I; Tentori C; Tondini CA; Grimes JM; Trager MH; Nahm S; Zubiri L; Manos M; Bowling P; Elkrief A; Papneja N; Vitale MG; Rose AAN; Borgers JSW; Roy S; Mangana J; Pimentel Muniz T; Cooksley T; Lupu J; Vaisman A; Saibil SD; Butler MO; Menzies AM; Carlino MS; Erdmann M; Berking C; Zimmer L; Schadendorf D; Pala L; Queirolo P; Posch C; Hauschild A; Dummer R; Haanen J; Blank CU; Robert C; Sullivan RJ; Ascierto PA; Miller WH; Stephen Hodi F; Suijkerbuijk KPM; Reynolds KL; Rahma OE; Lorigan PC; Carvajal RD; Lo S; Mandala M; Long GV
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33468556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.